Disclosed herein are mortal pluripotent stem cells produced in vitro and compositions thereof. Disclosed herein are methods of treating a disorder or condition by utilizing the cells disclosed herein. Also disclosed herein are methods of growing cells in culture medium as well as populations of mortal pluripotent stem cells differentiated therefrom.

The present invention provides a basal cell culture medium and a feed medium with novel amino acid ratios and/or iron choline citrate as iron carrier that result in improved performance of mammalian cell culture processes, such as CHO cultivation and protein production processes, in particular in increased product titer (e.g. of monoclonal antibodies). Also provided are methods for culturing mammalian cells and producing a protein of interest using said basal cell culture medium and optionally feed medium. The invention also provides for a medium platform that comprises (i) the basal cell culture medium and (ii) the feed medium.

A method of expanding and maintaining human embryonic stem cells (ESCs) in an undifferentiated state by culturing the ESCs in a suspension culture under culturing conditions devoid of substrate adherence is provided. Also provided are a method of deriving ESC lines in the suspension culture and methods of generating lineage-specific cells from ESCs which were expanded in the suspension culture of the present invention.

The specification describes an improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Ornithine, or a combination of ornithine and putrescine can be added to serum-free media or chemically defined media to improve viable cell density, to reduce cell doubling time, and to increase the production of a protein of interest.

The present invention relates to dry cell culture media comprising amino acid components of certain particle size. Some dry powder cell culture media show poor dissolving properties and result in turbid solutions when they are dissolved in aqueous solutions. Using amino acid components of certain particle sizes significantly reduces that problem.

Methods for generating human arterial endothelial cells under defined conditions in the absence of insulin are described. In particular, provided herein are efficient, defined, and scalable methods for generating human arterial endothelial cells from human pluripotent stem cells. Also provided herein are uses of human arterial endothelial cells obtained according to these methods. For example, methods of treating peripheral arterial disease and methods of screening agents for that effect adhesion of leukocytes to arterial endothelial cells are also provided.

Certain exemplary embodiments are directed to a biologically active composition of matter (and uses thereof) configured for targeted delivery of biotin to mitochondria, the composition comprising a first D-biotin conjugated to a water-soluble, cell-permeable, peptide sequence, wherein the peptide sequence is selected from a polypeptide group with an alternating aromatic-cationic motif.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Provided is a method for separating and extracting mesenchymal stem cells from the human umbilical cord. The method uses healthy neonatal umbilical cord tissue; after cleaning and disinfection, mechanically pulverising same, separating the Wharton's jelly, and after treating with erythrocyte lysate, carrying out suspension culture in a serum-free culture medium. Replacing the liquid every 3-5 days; after the plate adherence rate reaches 30-70%, carrying out trypsin digestion, and then collecting the cells by centrifugation for passage amplification, until the rate of confluence of the cells reaches 80-90% confluence, thereby obtaining high purity umbilical cord mesenchymal stem cells.

The present disclosure pertains compositions comprising anti-VEGF proteins and methods for producing such compositions.